Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder urothelium.

Mugabe C, Raven PA, Fazli L, Baker JH, Jackson JK, Liggins RT, So AI, Gleave ME, Minchinton AI, Brooks DE, Burt HM.

Biomaterials. 2012 Jan;33(2):692-703. doi: 10.1016/j.biomaterials.2011.09.081. Epub 2011 Oct 19.

PMID:
22014457
2.

In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer.

Mugabe C, Matsui Y, So AI, Gleave ME, Baker JH, Minchinton AI, Manisali I, Liggins R, Brooks DE, Burt HM.

Clin Cancer Res. 2011 May 1;17(9):2788-98. doi: 10.1158/1078-0432.CCR-10-2981. Epub 2011 Feb 28.

3.

In vitro and in vivo evaluation of intravesical docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols in an orthotopic model of bladder cancer.

Mugabe C, Matsui Y, So AI, Gleave ME, Heller M, Zeisser-Labouèbe M, Heller L, Chafeeva I, Brooks DE, Burt HM.

Biomacromolecules. 2011 Apr 11;12(4):949-60. doi: 10.1021/bm101316q. Epub 2011 Mar 1.

PMID:
21355626
4.

Development and in vitro characterization of paclitaxel and docetaxel loaded into hydrophobically derivatized hyperbranched polyglycerols.

Mugabe C, Liggins RT, Guan D, Manisali I, Chafeeva I, Brooks DE, Heller M, Jackson JK, Burt HM.

Int J Pharm. 2011 Feb 14;404(1-2):238-49. doi: 10.1016/j.ijpharm.2010.11.010. Epub 2010 Nov 17.

PMID:
21093563
5.

Synthesis and characterization of carboxylic acid conjugated, hydrophobically derivatized, hyperbranched polyglycerols as nanoparticulate drug carriers for cisplatin.

Ye L, Letchford K, Heller M, Liggins R, Guan D, Kizhakkedathu JN, Brooks DE, Jackson JK, Burt HM.

Biomacromolecules. 2011 Jan 10;12(1):145-55. doi: 10.1021/bm101080p. Epub 2010 Dec 3.

PMID:
21128674
6.

The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations.

Tsallas A, Jackson J, Burt H.

Cancer Chemother Pharmacol. 2011 Aug;68(2):431-44. doi: 10.1007/s00280-010-1499-2. Epub 2010 Nov 11.

PMID:
21069339
7.

Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy.

Mugabe C, Hadaschik BA, Kainthan RK, Brooks DE, So AI, Gleave ME, Burt HM.

BJU Int. 2009 Apr;103(7):978-86. doi: 10.1111/j.1464-410X.2008.08132.x. Epub 2008 Oct 31.

8.

Tissue Permeability Effects Associated with the Use of Mucoadhesive Cationic Nanoformulations of Docetaxel in the Bladder.

Pandey R, Jackson JK, Mugabe C, Liggins R, Burt HM.

Pharm Res. 2016 Aug;33(8):1850-61. doi: 10.1007/s11095-016-1920-6. Epub 2016 Apr 18.

PMID:
27091034
9.

Intravesical drug delivery: Challenges, current status, opportunities and novel strategies.

GuhaSarkar S, Banerjee R.

J Control Release. 2010 Dec 1;148(2):147-59. doi: 10.1016/j.jconrel.2010.08.031. Epub 2010 Sep 8. Review.

PMID:
20831887
10.

Investigation of hydrophobically derivatized hyperbranched polyglycerol with PEGylated shell as a nanocarrier for systemic delivery of chemotherapeutics.

Misri R, Wong NK, Shenoi RA, Lum CM, Chafeeva I, Toth K, Rustum Y, Kizhakkedathu JN, Khan MK.

Nanomedicine. 2015 Oct;11(7):1785-95. doi: 10.1016/j.nano.2015.04.016. Epub 2015 May 14.

PMID:
25981338
11.

Mucoadhesive polyacrylamide nanogel as a potential hydrophobic drug carrier for intravesical bladder cancer therapy.

Lu S, Neoh KG, Kang ET, Mahendran R, Chiong E.

Eur J Pharm Sci. 2015 May 25;72:57-68. doi: 10.1016/j.ejps.2015.03.006. Epub 2015 Mar 13.

PMID:
25772330
12.

EDTA-induced urothelial cell shedding for the treatment of superficial bladder cancer in the mouse.

Nativ O, Dalal E, Hidas G, Aronson M.

Int J Urol. 2006 Oct;13(10):1344-6.

13.

Design Considerations for Developing Hyperbranched Polyglycerol Nanoparticles as Systemic Drug Carriers.

Wong NK, Misri R, Shenoi RA, Chafeeva I, Kizhakkedathu JN, Khan MK.

J Biomed Nanotechnol. 2016 May;12(5):1089-100.

PMID:
27305828
14.

Permeability of pig urinary bladder wall: time and concentration dependent effect of chitosan.

Kos MK, Bogataj M, Veranic P, Mrhar A.

Biol Pharm Bull. 2006 Aug;29(8):1685-91.

15.

Bladder permeability barrier: recovery from selective injury of surface epithelial cells.

Lavelle J, Meyers S, Ramage R, Bastacky S, Doty D, Apodaca G, Zeidel ML.

Am J Physiol Renal Physiol. 2002 Aug;283(2):F242-53.

PMID:
12110507
16.

Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.

Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, Wheeler MA, Kelly WK, Tew GN, Saltzman WM, Weiss RM.

Nanomedicine. 2013 Nov;9(8):1124-34. doi: 10.1016/j.nano.2013.05.017. Epub 2013 Jun 11.

17.

Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy.

Lu Z, Yeh TK, Tsai M, Au JL, Wientjes MG.

Clin Cancer Res. 2004 Nov 15;10(22):7677-84.

18.

Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event.

Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR.

Toxicol Pathol. 2008 Feb;36(2):218-31. doi: 10.1177/0192623307311757.

PMID:
18474944
19.

A hydrotropic β-cyclodextrin grafted hyperbranched polyglycerol co-polymer for hydrophobic drug delivery.

Zhang X, Zhang X, Wu Z, Gao X, Cheng C, Wang Z, Li C.

Acta Biomater. 2011 Feb;7(2):585-92. doi: 10.1016/j.actbio.2010.08.029. Epub 2010 Sep 21.

PMID:
20813209
20.

Biocompatible hyperbranched polyglycerol modified β-cyclodextrin derivatives for docetaxel delivery.

Xu Z, Zhang Y, Hu Q, Tang Q, Xu J, Wu J, Kirk TB, Ma D, Xue W.

Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:965-972. doi: 10.1016/j.msec.2016.11.005. Epub 2016 Nov 4.

PMID:
27987795

Supplemental Content

Support Center